已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Comparative Drug Evaluation of Atorvastatin versus Rosuvastatin in Pharmacotherapy of Korean Patients with Dyslipidemia

作者
Seon‐Young Park,Myung-Koo Lee,Sung-Cil Lim
出处
期刊:Biomolecules & Therapeutics [Korean Society of Applied Pharmacology]
卷期号:16 (1): 54-60 被引量:2
标识
DOI:10.4062/biomolther.2008.16.1.054
摘要

Dyslipidemia is the multiple lipid metabolic disorders which is one of the high risk factors for the atherosclerotic diseases. It increases the morbidity and mortality and therefore, must be treated with antilipidemic agents. HMG-Co A reductase inhibitors (statins), one of many antidyslipidemic agents, have shown to be significant improvement from the various cholesterol levels. Especially, data from many comparative trials suggest that rosuvastatin is more effective than atorvastatin among many other statins. The aims of this study were to evaluate the efficacy and safety between rosuvastatin and atorvastatin in the treatment of Korean patients with dyslipidemia. Currently the Korean Society of Lipidology and Atherosclerosis based on the Korean health screening data suggests that Korean patients with dyslipidemia should be treated by the target cholesterol levels according to the Adult Treatment Panel III guidelines of the US National Cholesterol Education Program (NCEP-ATP III). We reviewed retrospectively all medical histories of the total 392 dyslipidemic patients with atorvastatin or rosuvastatin from June 1st, 2004 to August 31st, 2006 in Chungbuk National University Medical Center. Patients were classified as total 4 groups by the NCEP-ATP III Guidelines. The numbers of enrolled patients were each 5 mg atorvastatin (n=34), 10 mg atorvastatin (n=148), 5 mg rosuvastatin (n=94) and 10 mg rosuvastatin (n=82). In comparison between groups, rosuvastatin groups in the lowering LDL-C had better efficacies, and the results were each 22% (5 mg atorvastatin), 33.3% (10 mg atorvastatin), 35% (5 mg rosuvastatin) and 41.3% (10 mg rosuvastatin) with the dose relationship (P=0.000). Rosuvastatin groups also have shown to be more significantly reducing Total Cholesterol levels compared to atorvastatin groups with the no dose relationship (P=0.000). In the lowering of non-HDL cholesteroles, rosuvastatin groups showed significantly better efficacies than atorvastatin with the dose-relationship (P=0.000). Each medication groups did not demonstrate the differences in the changing of HDL cholesterol and triglyceride levels (P=0.096, 0.309, respectively). In conclusion, rosuvastatin was better efficacious than atrovastatin in reducing LDL-C Total Chol, and Tg. Therefore, rosuvastatin is a good antilipidemic agents for Korean patients with dyslipidemia and it can use to minimize the morbidity and mortality related to the cardiovascular diseases in Korean.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
王大壮完成签到,获得积分0
1秒前
almost发布了新的文献求助10
1秒前
3秒前
科研通AI6.3的应助被喜悦访烟采纳,获得10
5秒前
俏皮以旋发布了新的文献求助10
6秒前
6秒前
heaven发布了新的文献求助10
7秒前
LL完成签到 ,获得积分10
9秒前
小马甲的应助被SYX采纳,获得10
9秒前
rodion完成签到 ,获得积分10
9秒前
英姑的应助被uu采纳,获得10
10秒前
10秒前
坐雨赏花完成签到 ,获得积分10
10秒前
喜悦访烟完成签到,获得积分20
10秒前
小蘑菇的应助被研友_851KE8采纳,获得10
11秒前
almost完成签到,获得积分10
12秒前
刘萍完成签到 ,获得积分10
12秒前
12秒前
14秒前
不灵0发布了新的文献求助10
16秒前
16秒前
17秒前
18秒前
19秒前
19秒前
20秒前
11完成签到,获得积分10
20秒前
jinlin发布了新的文献求助10
20秒前
21秒前
SYX发布了新的文献求助10
22秒前
22秒前
23秒前
徐徐发布了新的文献求助10
23秒前
长情语蕊发布了新的文献求助30
23秒前
lll完成签到,获得积分20
24秒前
24秒前
滴嘟完成签到,获得积分10
25秒前
25秒前
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184619
求助须知:如何正确求助?哪些是违规求助? 9573576
关于积分的说明 21832380
捐赠科研通 7781845
什么是DOI,文献DOI怎么找? 3434399
关于科研通互助平台的介绍 2558498
邀请新用户注册赠送积分活动 2481003